2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 728

Autoimmune Hemolytic Anemia and Thrombocytopenia in a Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey : Clinical Associations and Effect on Disease Damage and Survival
Abstract Number: 729

The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus
Abstract Number: 730

Early Symptoms of Systemic Lupus Erythematosus As Reported By Members of the German Lupus Erythematosus Patient Association
Abstract Number: 731

Damage and Mortality in SLE: Cluster Analysis of Patients from SLE Registry from the Spanish Society for Rheumatology (RELESSER)
Abstract Number: 732

Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study
Abstract Number: 733

Late Onset Systemic Lupus Erythematosus: A Different Disease Subset?
Abstract Number: 734

Disease Patterns, Flare Incidence and Organ Damage Among Filipino Patients with Systemic Lupus Erythematosus: a One-Year Observational Study
Abstract Number: 735

Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting
Abstract Number: 736

Complement Activation As a Marker for Increased Thrombosis Risk in SLE Patients with Antiphospholipid Antibodies
Abstract Number: 737

A Paper Patient-Based Flare Study in SLE
Abstract Number: 738

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
Abstract Number: 739

Prednisone Increases Both Arterial and Venous Thrombosis in SLE
Abstract Number: 740

The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus
Abstract Number: 741

Satisfaction and Impact Associated with the Addition of Belimumab to Systemic Lupus Erythematosus (SLE) Treatment: A Cross-Sectional Survey of US Rheumatologists and Their Patients
Abstract Number: 742

IgM Antibodies Against Malondialdehyde and Phosphorylcholine Are T Cell Dependent and Strong Protection Markers for Atherosclerosis in SLE

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].